Pulnovo Medical secures $100 million in funding led by Medtronic
博动醫學獲美敦力領投 1 億美元融資
Pulnovo Medical, a pioneer in interventional cardiology, recently secured $100 million in an oversubscribed strategic financing round.
介入心臟病學先驅 Pulnovo Medical 近期在超額認購的戰略性融資中獲得了 1 億美元資金。
This major investment was led by Medtronic, a global leader in medical technology.
這筆重大投資由醫療技術領域的全球領導者美敦力 (Medtronic) 領投。
Along with the funding, the two companies entered a commercial agreement to explore future market opportunities.
除資金挹注外，兩家公司還達成了一項商業協議，共同探索未來的市場機會。
Founded in 2013, Pulnovo specializes in Pulmonary Artery Denervation (PADN), a minimally invasive procedure targeting nerves to treat pulmonary hypertension.
Pulnovo 成立於 2013 年，專注於肺動脈去神經支配術 (PADN)，這是一種透過標靶神經來治療肺動脈高壓的微創手術。
In the United States, their PADN system has earned FDA Breakthrough Device designation, and the company is currently conducting two IDE trials led by Dr.
在美國，他們的 PADN 系統已獲得 FDA 突破性醫療器材認定 (Breakthrough Device designation)，且該公司目前正進行由葛雷格·史東 (Dr.
Gregg Stone.
Gregg Stone) 博士領導的兩項 IDE 臨床試驗。
The new capital will be used to accelerate clinical trials and enhance international commercial infrastructure, signaling strong institutional confidence in their proprietary technology.
這筆新資金將用於加速臨床試驗並強化國際商業基礎設施，這顯示了市場對其專有技術的高度信心。
